ArticleHaematologica2022

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.

Tom Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.